Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Apixaban
Drug ID BADD_D00151
Description Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
Indications and Usage Apixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.
Marketing Status Prescription
ATC Code B01AF02
DrugBank ID DB06605
KEGG ID D03213
MeSH ID C522181
PubChem ID 10182969
NDC Product Code 0003-0893; 65129-1344; 55111-980; 50193-0893; 63629-8432; 16436-0113; 70366-001; 46708-908; 52048-0420; 63850-8085; 42816-0893; 14445-150; 59651-051; 53747-062; 65015-897; 55154-0613; 66174-0091; 76397-007; 75945-060; 24196-190; 15308-1221; 12783-0894; 66651-921; 63415-0520; 70518-1861; 66039-925; 65372-1196; 55154-0612; 12783-0893; 69989-0006; 76397-010; 42765-025; 76072-1017; 14501-0089; 67835-0015; 69037-0023; 50090-1437; 0003-0894; 58623-0137; 0003-3764; 42816-0894; 67296-1673; 58032-2028; 50090-1436; 65727-081; 14445-014; 63629-7747; 14445-149
Synonyms apixaban | Eliquis | BMS 562247 | BMS562247 | BMS-562247-01 | BMS-562247
Chemical Information
Molecular Formula C25H25N5O4
CAS Registry Number 503612-47-3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bile duct cancer16.07.01.001; Available
Bile duct stone09.02.02.0030.000662%Not Available
Bladder cancer20.03.04.001; Available
Bladder neoplasm20.03.04.002; Available
Bleeding time prolonged13.01.02.0020.000397%Not Available
Blindness06.02.02.001; Available
Blindness transient17.17.01.004; Available
Blindness unilateral17.17.01.016; Available
Blister23.03.01.001; Available
Blood albumin decreased13.09.01.001--Not Available
Blood bilirubin increased13.03.01.008--
Blood cholesterol increased13.12.01.002--
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine abnormal13.13.01.0020.001987%Not Available
Blood creatinine increased13.13.01.004--
Blood glucose abnormal13.02.02.008--Not Available
Blood glucose decreased13.02.02.001--Not Available
Blood glucose increased13.02.02.002--Not Available
Blood iron decreased13.11.01.006--Not Available
Blood lactate dehydrogenase increased13.04.02.002--
Blood potassium decreased13.11.01.010--Not Available
Blood pressure abnormal13.14.03.001--Not Available
Blood pressure decreased13.14.03.002--Not Available
Blood pressure fluctuation24.06.01.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood pressure systolic increased13.14.03.006--Not Available
Blood sodium decreased13.11.01.012--Not Available
Blood urea increased13.13.01.006--Not Available
Blood uric acid increased13.02.04.001--Not Available
Blood urine13.13.02.011--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 45 Pages